Abstract 277P
Background
Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, this seems too toxic for patients with frailty. Our study evaluated the efficacy and safety of tegafur/uracil (UFUR) associated with platinum and cetuximab (UPEx) in frail patients with R/M HNSCC.
Methods
Our study recruited frail patients who were aged > 70 years or performance status (PS) >2. Patients with a histologically confirmed R/M HNSCC unsuitable for locoregional curative therapy were treated with UPEx. The doses of UPEx were Tegafur 200mg twice per day for 14 days, cisplatin 30mg/m(2) at day 1 and cetuximab 500mg/m(2) at day 1, repeated every 2 weeks until progression or unacceptable toxicity. For patients with unfit renal function, carboplatin AUC =2 was used instead of cisplatin. The objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) was estimated.
Results
Forty-two patients were enrolled, including 81% aged > 70 years and 19% PS >2. The primary tumor mainly located in hypopharynx (43%) and oral cavity (43%), followed by oropharynx (10%) and larynx (4%). The ORR was 67%. Median OS and PFS were, respectively, 9.7 months (95% CI 7.4-11.9) and 5.8 months (95% CI 5.1-6.5). No patients had grade 3/4 adverse effects leading to discontinue treatment in our study.
Conclusions
The UPEx regimen was effective and tolerable as first-line treatment in frail patients with R/M HNSCC.
Clinical trial identification
Editorial acknowledgement
The authors thank the heda and neck cancer working group at E-Da hospital for their great assistance of data reviewing and examining.
Legal entity responsible for the study
Meng-che Hsieh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session